Physician profile
Kitrin Carpenter
NPI 1033118849
$2,439.67
in general payments reported to CMS, 2019-2025
34 companies · $624 in 2025
The $624 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $399 · 2023: $723 · 2024: $425 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $256.85 | 2022-2025 | Zeposia, Reblozyl |
| Pfizer INC. | $184.09 | 2023-2025 | |
| Glaxosmithkline, LLC. | $169.56 | 2023 | Zejula, Shingrix, Ojjaara |
| Seagen INC. | $167.88 | 2022-2023 | Adcetris, Padcev |
| Biogen, INC. | $156.86 | 2024-2025 | Vumerity, Tysabri |
| Incyte Corporation | $134.78 | 2021-2023 | Pemazyre, Monjuvi, Jakafi |
| Abbvie INC. | $128.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $127.67 | 2023-2025 | |
| Lilly USA, LLC | $115.27 | 2024-2025 | Kisunla, Amyvid, Zepbound |
| Alexion Pharmaceuticals, INC. | $102.32 | 2024-2025 | Ultomiris |
| Janssen Biotech, INC. | $99.00 | 2021 | |
| Lundbeck LLC | $83.69 | 2024-2025 | Vyepti |
| Eisai INC. | $80.52 | 2021-2025 | |
| Genzyme Corporation | $75.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $70.31 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $63.39 | 2022 | |
| Jazz Pharmaceuticals INC. | $47.53 | 2021-2025 | |
| Mirati Therapeutics, INC. | $38.19 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $33.02 | 2023 | Keytruda |
| Stemline Therapeutics INC. | $32.20 | 2023 | Orserdu |
| Amgen INC. | $29.21 | 2023 | Blincyto, Kyprolis, Evenity |
| Aveo Pharmaceuticals, INC. | $27.48 | 2023 | Fotivda |
| Dexcom, INC. | $21.88 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $20.75 | 2023 | |
| Celltrion USA INC. | $19.37 | 2023 | Vegzelma |
| Astellas Pharma US INC | $18.86 | 2023 | Xospata |
| Daiichi Sankyo INC. | $18.50 | 2023 | Injectafer |
| Neurocrine Biosciences, INC. | $17.72 | 2025 | |
| Genentech USA, INC. | $17.46 | 2024 | Ocrevus Zunovo |
| Sobi, INC | $17.43 | 2024 | |
| Kyowa Kirin, INC. | $17.12 | 2023 | Poteligeo |
| Digestive Care, INC. | $16.98 | 2025 | Pertzye |
| Sumitomo Pharma America, INC. | $16.22 | 2024 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kitrin Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.